Modular Medical, Inc.
For the period ended Mar 31, 2026. Filed Jun 29, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 29, 2026
MODD$1.67-9.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash Flows from operating activities | ||
| Net loss | $(28,242) | $(18,824) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,778 | 2,381 |
| Change in fair value of warrant liabilities | 835 | — |
| Depreciation and amortization | 1,672 | 1,063 |
| Shares issued for services | 11 | 51 |
| Other | (1) | 1 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other assets | (238) | (100) |
| Lease right-of-use assets | 402 | 370 |
| Accounts payable and accrued expenses | 453 | (288) |
| Lease liabilities | (423) | (374) |
| Net cash used in operating activities | (23,753) | (15,720) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (3,932) | (2,493) |
| Net cash used in investing activities | (3,932) | (2,493) |
| Cash flows from financing activities | ||
| Proceeds from issuance of promissory note | 250 | — |
| Repayment of promissory note | (250) | — |
| Proceeds from at-the-market sales of common stock, net | 1,882 | 2,114 |
| Proceeds from exercise of common stock warrants | 5 | 1,251 |
| Proceeds from offerings of common stock and warrants, net | 15,673 | 7,344 |
| Proceeds from private placement of common stock and warrants, net | — | 11,367 |
| Proceeds from warrant inducement offering, net | 3,972 | — |
| Net cash provided by financing activities | 21,532 | 22,076 |
| Net increase in cash and cash equivalents | (6,153) | 3,863 |
| Cash and cash equivalents, at beginning of year | 13,095 | 9,232 |
| Cash and cash equivalents, at end of year | $6,942 | $13,095 |
| Supplemental disclosure: | ||
| Noncash investing and financing activities: | ||
| Initial recognition of warrant liabilities | $2,030 | $— |
| Cash paid for: | ||
| Income taxes | $2 | $2 |
| Interest | $30 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.